A phase 1/1b dose-escalation trial evaluating CPI‐818, an oral interleukin‐2‐inducible T‐cell kinase inhibitor, in patients with relapsed/refractory T‐cell lymphoma Meeting Abstract
| Authors: | Mobasher, M.; Miller, R.; Janc, J.; Kwei, L.; Barker, C.; Mohammady, A.; Luciano, G.; Radeski, D.; Kim, Y.; Khodadoust, M.; Horwitz, S. |
| Abstract Title: | A phase 1/1b dose-escalation trial evaluating CPI‐818, an oral interleukin‐2‐inducible T‐cell kinase inhibitor, in patients with relapsed/refractory T‐cell lymphoma |
| Meeting Title: | 15th International Conference on Malignant Lymphoma |
| Journal Title: | Hematological Oncology |
| Volume: | 37 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2019 Jun 18-22 |
| Meeting Location: | Lugano, Switzerland |
| ISSN: | 0278-0232 |
| Publisher: | Wiley Blackwell |
| Date Published: | 2019-06-01 |
| Start Page: | 563 |
| End Page: | 564 |
| Language: | English |
| ACCESSION: | 136932379 |
| DOI: | 10.1002/hon.11_2632 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cin20 |
| PUBMED: | 31187525 |
| DOI/URL: | |
| Notes: | Meeting abstract: OT18 -- Accession Number: 136932379 -- Entry Date: In Process -- Revision Date: 20190617 -- Publication Type: Article -- Supplement Title: Jun2019 Supplement S1 -- Journal Subset: Biomedical; Europe; Peer Reviewed; UK & Ireland -- NLM UID: 8307268. -- Source: cin20 |
